Ronald Vogels

USPTO Granted Patents = 50 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 3.2

ph-index = 14

Forward Citations = 595(Granted Patents)

Forward Citations (Not Self Cited) = 452(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Linschoren, NL (2002)
Linschoten, NL (2002 - 2024)

Company Filing History:

Janssen Vaccines & Prevention B.v.

patents

3 out of 18

Aeras Global Tb Vaccine Foundation

patents

4. 2 out of 2

Galapagos Genomics N.v.

patents

5. 2 out of 8,369

Massachusetts Institute of Technology

Galapagos Geonomics N.v.

patent

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11964007 - Methods and compositions for heterologous repRNA immunizations (2024-04-23),

2. 11322228 - Structure based design of d-protein ligands (2022-05-03),

3. 11235051 - Methods and compositions for heterologous repRNA immunizations (2022-02-01),

4. 11136379 - Binding molecules directed against influenza hemagglutinin and uses thereof (2021-10-05),

5. 10703804 - Binding molecules directed against influenza hemagglutinin and uses thereof (2020-07-07),

6. 10370435 - Binding molecules directed against influenza hemagglutinin and uses thereof (2019-08-06),

7. 9969778 - Influenza virus vaccines and uses thereof (2018-05-15),

8. 9593159 - Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses (2017-03-14),

9. 9452211 - Influenza virus vaccines and uses thereof (2016-09-27),

10. 9228205 - Complementing cell lines (2016-01-05),

11. 9200064 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2015-12-01),

12. 9005621 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2015-04-14),

13. 8961978 - Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses (2015-02-24),

14. 8852595 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2014-10-07),

15. 8834881 - Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof (2014-09-16),

Title: The Innovative Contributions of Ronald Vogels

Introduction

Ronald Vogels, based in Linschoten, Netherlands, is a prolific inventor with a remarkable portfolio of 50 patents. His work primarily focuses on advancements in immunization methods and protein design, paving the way for breakthroughs in healthcare and biotechnology.

Latest Patents

Among Vogels' most notable recent patents is a groundbreaking method for heterologous repRNA immunizations. This innovative composition combines an in vitro transcribed self-replicating RNA (repRNA) with an adenovirus vector to effectively induce immune responses in humans. This technology has promising applications in providing protective immunity against various diseases, including viral infections and cancer. Another significant patent is his structure-based design of D-protein ligands. This method entails creating D-polypeptides that can bind to L-target proteins, which is pivotal in drug design and therapeutic development.

Career Highlights

Ronald Vogels has significantly impacted the biotechnology field through his association with notable companies. He has worked at Crucell Holland B.V., a biopharmaceutical company focused on the development of vaccines and antibody therapies. Additionally, he has contributed his expertise at Janssen Vaccines & Prevention B.V., where his innovations aim to enhance vaccination strategies.

Collaborations

Throughout his career, Vogels has collaborated with esteemed colleagues, including Abraham Bout and Menzo Jans Emco Havenga. These collaborations have played a crucial role in the refinement and success of his inventive methodologies, further advancing research in the biomedical field.

Conclusion

Ronald Vogels' contributions to the field of immunization and protein design underscore the importance of innovation in advancing medical science. His extensive patent portfolio not only reflects his ingenuity but also serves as a foundation for future advancements that could significantly impact healthcare and disease prevention.

This text is generated by artificial intelligence and may not be accurate.